Oramed Pharmaceuticals
ORMP
44 hedge funds and large institutions have $12.6M invested in Oramed Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 17 increasing their positions, 4 reducing their positions, and 8 closing their positions.
325% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 4
103% more capital invested
Capital invested by funds: $6.18M → $12.6M (+$6.37M)
64% more call options, than puts
Call options by funds: $3.92M | Put options by funds: $2.39M
63% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 8
13% more funds holding
Funds holding: 39 → 44 (+5)
1.94% less ownership
Funds ownership: 6.15% → 4.21% (-1.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.09M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$561K |
| 3 |
SPIA
Steward Partners Investment Advisory
New York
|
+$492K |
| 4 |
ECM
ExodusPoint Capital Management
New York
|
+$431K |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$219K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JSMC
Jess S. Morgan & Co
Los Angeles,
California
|
-$1.62M |
| 2 |
Renaissance Technologies
New York
|
-$1.58M |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$230K |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$206K |
| 5 |
Squarepoint
New York
|
-$129K |
ORMP Hedge Fund Activity: Q1 2021 in Review
44 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q1 2021, worth a combined $12.6M — up 103% from $6.18M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new ORMP positions and 8 closed out — a net gain of 5 holders — while 17 added to existing stakes and 4 trimmed.
The largest buyer was Millennium Management, adding an estimated $1.09M. The largest seller was Jess S. Morgan & Co, cutting an estimated $1.62M.
- 44 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q1 2021, up from 39 in Q4 2020.
- Funds reported $12.6M of Oramed Pharmaceuticals stock for Q1 2021, up 103% quarter-over-quarter.
- 13 funds opened new Oramed Pharmaceuticals positions in Q1 2021 and 8 closed out, a net change of +5 holders.
- The largest Oramed Pharmaceuticals buyer in Q1 2021 was Millennium Management, an estimated $1.09M added.
- The largest Oramed Pharmaceuticals seller in Q1 2021 was Jess S. Morgan & Co, an estimated $1.62M sold.
Based on aggregated 13F filings for Q1 2021.